Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | GAK | O14976 | 9/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 3/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.37 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2215329 | 0.89 | ERN1 (0.46) | GAKKDM4EHPGDHTTERN1 | |
| SCHEMBL2216045 | 0.86 | ALDH1A1 (0.37) | LRRK2GAKKDM4EHTTPIK3CD | |
| SCHEMBL2214156 | 0.83 | GAK (0.38) | LRRK2GAKKDM4EHPGDHTT | |
| SCHEMBL2216042 | 0.82 | GAK (0.41) | LRRK2GAKKDM4EERN1PIK3CD | |
| SCHEMBL2212992 | 0.80 | ERN1 (0.44) | CYP11B2GAKKDM4EERN1PIK3CD | |
| SCHEMBL2216454 | 0.80 | LRRK2 (0.46) | LRRK2GAKABL1KDM4EHTT | |
| SCHEMBL2214872 | 0.78 | TDP1 (0.40) | LRRK2CYP11B2GAKKDM4EHTT | |
| SCHEMBL2213873 | 0.78 | LRRK2 (0.40) | LRRK2GAKKDM4EHPGDHTT | |
| SCHEMBL2215288 | 0.78 | L3MBTL1 (0.44) | GAKKDM4EHPGDPIK3CA | |
| SCHEMBL2215416 | 0.77 | GAK (0.52) | GAKKDM4EHPGDHTTPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178064-A1 | SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL | ASTRAZENECA R&D (SE) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178064-A1 | SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL | TBCA, TUBA1A, BROX | LRRK2 414/4885CYP11B2 206/4885GAK 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.